EP1476461A2 - Peptide de modulation de l'immunite issu de l'enterotoxine b de i s. aureus - Google Patents

Peptide de modulation de l'immunite issu de l'enterotoxine b de i s. aureus

Info

Publication number
EP1476461A2
EP1476461A2 EP03704622A EP03704622A EP1476461A2 EP 1476461 A2 EP1476461 A2 EP 1476461A2 EP 03704622 A EP03704622 A EP 03704622A EP 03704622 A EP03704622 A EP 03704622A EP 1476461 A2 EP1476461 A2 EP 1476461A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
seq
sequence
production
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03704622A
Other languages
German (de)
English (en)
Inventor
Karsten Neuber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AgeLab Pharma GmbH
Original Assignee
AgeLab Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10207734A external-priority patent/DE10207734A1/de
Priority claimed from DE10240866A external-priority patent/DE10240866A1/de
Application filed by AgeLab Pharma GmbH filed Critical AgeLab Pharma GmbH
Publication of EP1476461A2 publication Critical patent/EP1476461A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates in particular to peptides which are capable of specifically binding IgE antibodies and which are obtainable, for example, from the naturally occurring S. aureus enterotoxin B (SEB). Their immunomodulatory properties differ significantly from those of the bacterial SEB. In contrast to SEB, the peptides according to the invention surprisingly do not induce proliferation of T cells.
  • SEB S. aureus enterotoxin B
  • the peptides are suitable for the therapy of diseases which are characterized by an increased serum IgE level and / or an increased production of interferon-gamma, and for the therapy of diseases which are characterized by an imbalance of Thl and Th2 immune response are characterized, such as atopic eczema, lupus ery- thematodes, Crohn's disease, multiple sclerosis, psoriasis, rheumatoid arthritis.
  • Staphylococcus aureus is a widespread pathogenic microorganism that can trigger a variety of serious infectious diseases.
  • S. aureus produces enterotoxins (enterotoxin A, B, C, D, E and TSST-1) and endotoxins (coagulase, staphylokinase, lipase, hyaluronidase, DNAse). Due to the development of multiple resistance to various antibiotics, S. aureus has become very important in recent years as a causative agent of hospital infections.
  • the enterotoxins (SE) produced by S. aureus can be Trigger food poisoning and septic shock [Marrack, P. & Kappler, J. (1990), Science 248, 705].
  • SEA staphylococcal enterotoxin A
  • SEE staphylococcal enterotoxin E
  • T- Cell repertoire can be stimulated in vivo by bacterial superantigens [Choi, Y. (1990), ". Exp. Med. 172, 981].
  • These T- Cell stimulation induces an abundance of complex pathophysiological mechanisms that have not yet been fully elucidated.
  • intoxication with superantigens leads to sy- stemmic reactions, which can range from fever to cardiovascular shock [Fleischer, B. (1991), Immun. Infection. 19, 8].
  • Table 1 shows the immunological reactions induced by S. aureus enterotoxins. These reactions are likely to be triggered by complex immunological processes.
  • CLA cutaneous lymphocyte-associated antigen
  • Tab. 1 Immunological reactions induced by S. aureus enterotoxins. After this hyperactive phase, the superantigen-stimulated T cells change into an anergic state, so that massive immunosuppression can occur. On the other hand, autoreactive but anergic T cells can be activated, which then trigger autoimmune diseases. With multiple sclerosis [Hafler, DA (1988), J. Exp. Med. 167, 1313] and rheumatoid arthritis [Palliard, X. (1991), Science 253, 325], an oligoclonal selection of certain V E chains has already been made detected, which indicates a superantigen-mediated pathomechanism of these diseases.
  • SEB increases the IgE synthesis and the production of interleukin-4 in patients with atopic eczema [Neuber, K, (1993), dermatologist 44, 135; Ring, J. et al. (1992) Allexgy 47, 265; Neuber, K. et al. (1995), Int. Arch. Allergy Im unol. 107, 179].
  • an eczema-inducing effect for SEB was demonstrated in the patch test [Hofer, M.F. (1999), J. Invest. Dermatol. 112, 171].
  • atopic eczema is one of the diseases in which pathologically increased IgE synthesis occurs. So far, these diseases can only be treated symptomatically, ie the suppression of IgE synthesis takes place unspecifically through the suppression of the T lymphocytes involved in the synthesis.
  • the most common systemically used drugs are cortisone or cyclosporin A. These substances often cause very serious systemic side effects (skin atrophy, diabetes, hypertension, kidney and hepatotoxicity, etc.). Such specific side effects would be avoided by a specific modulation of the excessive IgE synthesis. The same also applies to diseases which are accompanied by an increased interferon-gamma synthesis of the lymphocytes.
  • a good example of such a condition is psoriasis vulgaris. reduce T-cells more interferon-gamma and thereby induce the hyperproliferation of the epidermis.
  • Immunosuppressants such as cortisone or cyclosporin A are also used to treat psoriasis. In this case, the selective inhibition of cytokine production would also significantly reduce the rate of side effects.
  • Thl or a weakened Th2 reaction has been causally proven or is being discussed in a number of diseases (see also Table 2). Experimental animal findings suggest that these.
  • Organ-specific autoimmune diseases such as multiple sclerosis are to be mentioned here [Shevach, EM et al. (1999), Springer Semin. Immunopathol. 21, 249-262; Leonard, JP et al. (1997), Grit. Rev. Immunol. 17, 545-553], autoimmune uveitis [Singh, VK et al. (1999), Immunol. Res. 20, 147-161; Sun, B. et al. (1999), Int. Immunol. 11, 1307-1312; Egwuagu, CE et al. (1999), J. Immunol.
  • the object of the present invention is therefore to provide a new active ingredient which is suitable for the treatment of diseases which are characterized by an increased IgE level and / or an increased interferon gamma production and which do not have the disadvantages known in the prior art ,
  • peptides can be isolated from the naturally occurring S. aureus enterotoxin B (SEB) which achieve the above-mentioned objects.
  • SEB S. aureus enterotoxin B
  • a peptide can be isolated which is capable of specifically binding IgE antibodies.
  • its immunomodulatory properties differ considerably from those of the bacterial SEB.
  • the peptide according to the invention the amino acid sequence of which is shown in SEQ ID NO: 10, surprisingly does not induce proliferation of T cells, but on the other hand inhibits the interferon-gamma synthesis of stimulated T lymphocytes.
  • the peptide is suitable for the therapy of diseases which are characterized by increased serum IgE levels and / or increased production of interferon gamma.
  • the diseases are preferably allergic rhinoconjunctivitis, allergic bronchial asthma and psoriasis vulgaris.
  • peptides according to the invention were produced which have the same or essentially the same biological and / or immunological properties. Because of their special properties, ie binding of IgE antibodies and inhibition of interferon gamma Synthesis without induction of T cell proliferation, the peptides according to the invention are particularly suitable for the treatment of diseases which are associated with increased IgE synthesis and increased interferon-gamma synthesis, as is the case, for example, with atopic eczema (neurodermatitis) , This condition has been described in the chronic course of atopic eczema. Interferon gamma-producing T lymphocytes are found in the skin and there are increased serum IgE values.
  • the therapeutic effect of the peptides could either be achieved directly by an inactivating binding to the IgE, or indirectly by modulating the cytokine production of the T lymphocytes.
  • inhibition of other cytokines such as IL-4 and IL-13 are also considered, which are known to stimulate IgE synthesis.
  • the present invention therefore relates to a polypeptide which has the N-terminal amino acid sequence as shown in SEQ ID NO: 15 and which can be obtained by trypsin cleavage of S. aureus enterotoxin B as a 12 kD cleavage fragment.
  • the invention relates to a polypeptide (hereinafter referred to as peptide P1) which has the amino acid sequence given in SEQ ID NO: 10 and which inhibits the synthesis of interferon-gamma by stimulated T lymphocytes in vitro.
  • the present invention further includes homologs and derivatives of the aforementioned polypeptides that bind to IgE.
  • the homologous polypeptides are substances which, however, differ from the aforementioned amino acid sequences, in particular from the sequence according to SEQ ID NO: 10, as a result of the exchange of one or more amino acids or by insertion or deletion of one or more amino acids, wherein they have a sequence homology of about 50 to 99%, preferably at least about 75%.
  • a sequence homolo gie of at least 85% is particularly preferred.
  • a derivative is understood to mean those polypeptides in which one or more amino acids of the aforementioned sequences, in particular the sequence according to SEQ ID NO: 10, are replaced by a stereoisomer (ie replacement of one or more L-amino acids by D-amino acids) or a corresponding one , modified amino acid are exchanged.
  • Modified amino acids are understood to mean those amino acids whose side chains are chemically changed compared to naturally occurring amino acids, for example by glycosylation,
  • the homologs and derivatives which bind IgE have the same or essentially the same properties as the aforementioned peptide according to SEQ ID NO: 10, i.e. they inhibit the synthesis of interferon-gamma stimulated T lymphocytes in vitro and / or they do not induce the proliferation of T lymphocytes.
  • the homolog (hereinafter referred to as peptide P2) has the amino acid sequence given in SEQ ID NO: 11.
  • the invention also includes polypeptides with a length of more than 9 amino acids which contain the amino acid sequence given in SEQ ID NO: 10 or 11 and which inhibit the synthesis of interferon-gamma by stimulated T-lymphocytes in vitro.
  • the invention further relates to a nucleic acid molecule which contains a nucleic acid sequence coding for a aforementioned polypeptide. It preferably has the nucleic acid sequence given in SEQ ID NO: 9.
  • the nucleic acid molecule can be used to convert the sequence into an expression vector to clone in and to produce the peptide according to the invention recombinantly. These methods are well known to those skilled in the art.
  • the peptides according to the invention are able to influence the ratio between Thl and Th2 cells and thus also the ratio of the corresponding cytokines.
  • Tab. 2 Diseases with an imbalance in the TH1 / TH2 ratio, which are suitable for therapy with the peptides.
  • these are particularly suitable for the production of a pharmaceutical composition for inducing or enhancing a Thl or Th2 immune response by increasing the Th2 or lowering the Thl response and vice versa, in particular for producing a pharmaceutical composition for the treatment of diseases associated with a (predominant) Th2 or Thl immune response.
  • diseases selected from the group consisting of multiple sclerosis, autoimmune uveitis, diabetes mellitus, rheumatoid arthritis, Behcet ⁇ s syndrome, helicobacter pylori infection, inflammatory bowel diseases (Crohn's -and- -Crohn) - akuter- Organ transplant rejection and spontaneous recurrent abortions.
  • the invention furthermore relates to the use of a polypeptide which has or contains the amino acid sequence according to SEQ ID NO: 10 for the production of a pharmaceutical composition for immunomodulation and for inhibiting the cytokine production of lymphocytes, in particular T-lymphocytes. Also included is the use of such a polypeptide for the manufacture of a pharmaceutical composition for the treatment of diseases associated with an increased production of cytokines (such as interferon-gamma) and / or an increased level of IgE antibodies.
  • the diseases are, in particular, atopic eczema (especially in the chronic form), bronchial asthma, allergic rhinoconjunctivitis, psoriasis, rheumatoid arthritis or multiple sclerosis.
  • the cytokine is interferon-gamma, interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-10 (IL-10), interleukin-12 (IL- 12) and / or interleukin-13 (IL-13).
  • IL-4 interleukin-4
  • IL-5 interleukin-5
  • IL-10 interleukin-10
  • IL-12 interleukin-12
  • IL-13 interleukin-13
  • the present invention includes the use of a polypeptide described above which has an amino acid sequence homologous to or derived from SEQ ID NO: 10.
  • a polypeptide described above which has an amino acid sequence homologous to or derived from SEQ ID NO: 10.
  • the homologous or sequences derived therefrom reference is made to the above definition of the "homologues” and “derivatives”, including in particular those IgE-binding polypeptides which do not induce the proliferation of T lymphocytes and / or in vitro the synthesis of Inhibit interferon gamma by stimulated T lymphocytes.
  • the polypeptide used has the sequence according to SEQ ID NO: 11.
  • polypeptides which contain the sequence according to SEQ ID NO: 10 or SEQ ID NO: 11 or sequences homologous therefrom or derived therefrom. with “the same or essentially the same biological or immunological properties as part of a longer amino acid sequence, polypeptides with a length of up to 30 amino acids, in particular with a length of up to 15 amino acids, are preferred.
  • polypeptides according to the invention are suitable for in vitro inhibition of interferon gamma production in lymphocytes, in particular in human, peripheral T-lymphocytes of the blood.
  • the peptides according to the invention modulate both the stimulated and the spontaneous cytokine production of TH1 and TH2 lymphocyte subpopulations.
  • the endogenous activation status of the lymphocytes seems to play an important role in the direction of the peptide-induced effects.
  • an inhibition of the endogenously increased synthesis of all cytokines by the peptide P1 according to the invention is observed.
  • an increased IFN ⁇ production is observed especially in the chronic inpatient form.
  • the peptide P1 according to the invention in particular is able not only to inhibit the TH2 cytokine synthesis of the lymphocytes of these patients, but also the IFN ⁇ production, which is of considerable therapeutic relevance, for example by alleviating the symptoms until healing.
  • IL-10 can have a beneficial effect on the clinical appearance of psoriasis.
  • the targeted effect of the peptides according to the invention on the IL-10 production of the lymphocytes of psoriasis is of particular therapeutic importance in the interaction with the effects on the other cytokines, e.g. by alleviating the symptoms until healing.
  • the invention further relates to a pharmaceutical composition which contains one or more polypeptides according to the invention as an active ingredient and optionally also one or more pharmaceutically acceptable auxiliaries and / or carriers.
  • the peptide isolated from SEB can be obtained by digesting enterotoxin B from S. aureus with trypsin and then isolating the 12 kD fragment from the reaction mixture.
  • genetic engineering methods of production are of course also possible by introducing the nucleic acid sequence shown in SEQ ID NO: 9 into an expression vector, introducing this into suitable host cells, cultivating the host cells under conditions which lead to protein expression. are suitable and the expressed polypeptide is isolated, which is encoded by the nucleic acid sequence.
  • Example 1 Immunoblot for the detection of specific IgE antibodies against SEB.
  • the gel electrophoretic separation of proteins was carried out according to the method of Lughtenberg et al. [Lughtenberg, B. (1975), FEBS Lett. 58, 254]. 12.5% polyacrylamide release gels were used. Standard protein mixtures (Biorad, MW standard, 203 kD - 7.5 kD) were separated in parallel to determine the molecular weights. The proteins were stained with Coomassie-Blue G-250. 10 bags were available in the collection gel for sample collection, the amount of protein used being between 10 and 100 ⁇ g. The protein solution to be separated (20 ⁇ l) was mixed with 20 ⁇ l sample buffer, filled into the collecting egg pockets and then covered with an electrode buffer.
  • the electrophoresis was carried out in electrode buffer and with a constant current flow of 20 mA.
  • the electrophoresis was stopped.
  • the protein mixtures to be examined were separated by gel electophoresis (SDS-PAGE) and transferred to nitrocellulose (pore size 0.45 ⁇ m) using the Western blot method.
  • the transfer took place with cooling in an electro-blot chamber (BioRad, Kunststoff) immediately after the gel electrophoresis for 18-20 h at a constant current of 0.2-0.3 A.
  • the nitrocellulose blots were incubated with human serum for 4 h on a swivel table at RT (Dianova, Hamburg).
  • the blots were then washed five times and then again incubated for 4 h at RT with a secondary antibody against human IgE (anti-human IgE antibody, from Serva, Heidelberg) and the binding was visualized by an enzymatic color reaction.
  • human IgE anti-human IgE antibody, from Serva, Heidelberg
  • Peroxidase-labeled antibodies were used in the immunoblots. It should be noted that the result of the blot (in scanned form) shown in FIG. 1 does not correspond to the actual color gradations that can be seen with the naked eye. The bands to be recognized as shadows on the original blot are so weak compared to the bands incubated with atopic sera that they have to be considered as non-specific reactions.
  • SEB 100 ⁇ g / 100 ⁇ l was digested enzymatically with 10 ⁇ l trypsin (4 mg / ml aqua dest.) At 37 ° C. for 18 h. The solution was then applied to SDS gels and the corresponding cleavage products separated. The conditions for the gel electrophoresis corresponded to the conditions given in Example 1. The cleavage products were incubated in the immunoblot with sera from the patients with atopic eczema mentioned in Example 1. Serum from healthy control persons served as a control. The result of the trypsin digestion is shown in Figure 2.
  • the cleavage product, identified as IgE binding, with a molecular weight of approximately -12 kD was eluted from the gel and then mechanically according to the method of P. Edman [Edman, P. (1950), Acta Chem. Scand , 4, 283], the N-terminal sequence KVTAQELDYL being determined.
  • the sequence analysis thus revealed a sequence that begins at position 181 (from the N-terminal end) of the SEB molecule.
  • Figure 3 shows the result of the sequence analysis.
  • the two peptides according to the invention can bind IgE antibodies from the serum of patients with atopic eczema.
  • the sera from 5 different patients with atopic eczema were first pre-cleaned using protein G columns (1 ml, Pharmacia). The sera were prefiltered through 0.8 ⁇ m syringe heads. The column was then coupled with 10 ml of binding buffer (20 mM PBS, pH 7.0) “drop to drop” and washed at a flow rate of 1 ml / min.
  • PBMC Peripheral blood lymphocytes
  • PBMC Peripheral blood lymphocytes
  • SEB (1 ⁇ g / 10 6 cells) and the peptide (5 ⁇ g / 10 6 cells) were used as stimuli.
  • the proliferation of the cells and the intracellular production of interferon-gamma and interleukin-4 were measured by flow cytometry after 2 days of incubation at 37 ° C. and 5% CO 2 .
  • the peripheral blood lymphocytes were isolated by a Ficoll-Paque gradient centrifugation, the cell number was adjusted to 2 ⁇ 10 6 cells / ml.
  • the cells were taken up in 15 ml conical polypropylene tubes and then incubated in the incubator for 2 days.
  • the PBMC were incubated with 60 ⁇ M bromodeoxyuridine (BrdU) in the last 5 h of the incubation period.
  • PrdU bromodeoxyuridine
  • the proliferation was determined by the incorporation of BrdU in lymphocytes on the flow cytometer.
  • the incubation of the lymphocytes with different concentrations of the peptides P1 and P2 according to the invention showed no significant effects of the peptides on the proliferation (FIG. 6A).
  • the SEB-induced proliferation was neither significantly modified by the peptides alone (FIG. 6A) nor by the costimulation with SEB + peptide PI (FIG. 6B).
  • the SEB-induced lymphocyte proliferation was inhibited only in high concentrations (FIG. 6B).
  • the intracellular IFN ⁇ (FIG. 7) and IL-4 production after stimulation with SEB and the peptides P1 and P2 according to the invention were examined (FIG. 7).
  • Example 7 Effect of the peptides on secretory cytokine production
  • Peripheral blood lymphocytes from healthy voluntary donors were isolated using a Ficoll gradient and taken up in a concentration of 10 s cells / ml in RPMI 1640 medium + 10% FCS (fetal calf serum). The cells were seeded in 24-well plates and with the beiden- - incubating peptides (200 ⁇ ug / 10 6 cells.) For 2 days in an incubator (37 ° C, 5% C0 2). The supernatants were then collected and first frozen at -20 ° C.
  • the human TH1 cytokines IL-2, IFN ⁇ and TNF ⁇ as well as the TH2 cytokines IL-4, IL-5 and IL-10 were in the cell culture supernatant with the "Cytometric Bead Array (CBA)" ⁇ from the company B&D (Heidelberg) The test was carried out exactly according to the manufacturer's instructions.
  • CBA Cytometric Bead Array
  • Pl mainly inhibits the spontaneous production of the TH1 cytokines IL-2 and IFN ⁇ , while P2 inhibits TNF ⁇ more strongly.
  • Peptide 2 induces the synthesis of TH2 cytokines (IL-4, IL-5, IL-10) in healthy volunteers, while PI also completely inhibits the synthesis of IL-4 and IL-5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

La présente invention concerne des peptides particuliers qui sont capables de provoquer la liaison spécifique d'anticorps IgE et qui peuvent être obtenus par exemple à partir de l'entérotoxine B de S. aureus d'origine naturelle. Leurs propriétés de modulation de l'immunité se différentient considérablement de celles des bactéries SEB. Des peptides de l'invention, contrairement aux SEB, n'induisent étonnamment aucun prolifération de lymphocytes T. En raison de leur propriétés, les peptides conviennent à la thérapie de maladies qui se caractérisent par un taux d'IgE sérique trop élevé et/ou une production accrue d'interférons gamma, ainsi qu'à la thérapie de maladies qui se caractérisent par un déséquilibre des réponses immunitaires Th1 et Th2, ainsi que de l'eczéma atopique, du lupus érythémateux, de la maladie de Crohn, de la sclérose en plaques, du psoriasis, et de l'arthrite rhumatoïde..
EP03704622A 2002-02-15 2003-02-14 Peptide de modulation de l'immunite issu de l'enterotoxine b de i s. aureus Withdrawn EP1476461A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10207734 2002-02-15
DE10207734A DE10207734A1 (de) 2002-02-15 2002-02-15 Immunmodulierendes Peptid aus S. aureus Enterotoxin B
DE10240866 2002-09-04
DE10240866A DE10240866A1 (de) 2002-09-04 2002-09-04 Immunmodulierendes Peptid aus S. aureus Enterotoxin B
PCT/EP2003/001511 WO2003068812A2 (fr) 2002-02-15 2003-02-14 Peptide de modulation de l'immunite issu de l'enterotoxine b de s. aureus

Publications (1)

Publication Number Publication Date
EP1476461A2 true EP1476461A2 (fr) 2004-11-17

Family

ID=27735690

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03704622A Withdrawn EP1476461A2 (fr) 2002-02-15 2003-02-14 Peptide de modulation de l'immunite issu de l'enterotoxine b de i s. aureus

Country Status (5)

Country Link
US (1) US20060127411A1 (fr)
EP (1) EP1476461A2 (fr)
JP (1) JP2005531289A (fr)
AU (1) AU2003206900A1 (fr)
WO (1) WO2003068812A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2531261A1 (fr) * 2005-12-21 2007-06-21 Institut Pasteur Traitement de syndromes d'inflammation intestinale a l'aide d'une preparation a base de bacteries tuees ou non infectieuses
EP2295972A1 (fr) * 2009-09-10 2011-03-16 Biomay Ag Allergènes s. aureus
JP5439127B2 (ja) * 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
KR102157718B1 (ko) 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 면역원성 소염 조성물
WO2015164979A1 (fr) 2014-05-02 2015-11-05 Qu Biologics Inc. Immunomodulation anti-microbienne

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024136A1 (fr) * 1991-01-17 1993-12-09 Terman David S Effets tumoricides des enterotoxines, superantigenes et composes apparentes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03068812A2 *

Also Published As

Publication number Publication date
WO2003068812A2 (fr) 2003-08-21
US20060127411A1 (en) 2006-06-15
AU2003206900A1 (en) 2003-09-04
JP2005531289A (ja) 2005-10-20
WO2003068812A3 (fr) 2004-01-08

Similar Documents

Publication Publication Date Title
DE69028671T3 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
DE69518156T2 (de) Immunomodulatoren
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
DE60132893T2 (de) Antigene polypeptide
DE69429176T2 (de) Protegrine
DE3751553T2 (de) Immunomodulare mittel und deren verwendung.
DE69224524T2 (de) Antimikrobielle breitspektrum-verbindungen und verfahren zu deren verwendung
DE3781078T2 (de) Verwendunng eines peptids zur herstellung von zusammensetzungen fuer die linderung, behandlung und diagnose von autoimmunkrankheiten, insbesondere arthritis, zu diesem peptid analoge verbindungen, mikro-organismen, die dieses peptid oder eine zu diesem peptid analoge verbindung produzieren, als auch pharmazeutische und diagnostische zusammensetzungen und test kits.
DE2450355A1 (de) Aus n-acyl-muraminsaeurederivaten gebildete adjuvanzien und diese enthaltende impfstoffe
DE69937798T2 (de) Peptide, basierend auf der sequenz des menschlichen lactoferrins und ihre anwendung
DE10212108A1 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE69320967T2 (de) Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
EP1600164A2 (fr) Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
DE69104602T2 (de) Stressprotein aus bakterien.
DE69734141T2 (de) PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
Prinz et al. Allergen‐directed expression of Fc receptors for IgE (CD23) on human T lymphocytes is modulated by interleukin 4 and interferon‐γ
DE69006676T2 (de) Tripeptidverbindungen und ihre pharmazeutische Anwendung als Immunmodulatoren.
DE69737659T2 (de) Peptide aus t-zellepitopen
DE69433115T2 (de) Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
DE60028248T2 (de) Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
EP1476461A2 (fr) Peptide de modulation de l'immunite issu de l'enterotoxine b de i s. aureus
DE3688337T2 (de) Polypeptidfaktoren aus Kolostrum.
DE19713001A1 (de) Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
DE69505376T2 (de) Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
DE69931784T2 (de) Chemotaxishemmendes protein von staphylococcus aureus (chips) und dessen verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040913

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NEUBER, KARSTEN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061218